Nabla Bio

Nabla Bio harnesses AI-driven computational modeling and cutting‑edge wet‑lab techniques to rationally design developable, selective therapeutics for targets that have historically been considered undruggable. The company partners with major pharmaceutical players—including AstraZeneca, Bristol Myers Squibb, and Takeda—to enrich their pipelines with high‑quality candidates, aiming to double the number of disease‑relevant targets brought to market. Since its 2021 launch, Nabla Bio has secured $37 million from investors such as Radical Ventures, Khosla Ventures, and Zetta Venture Partners, and its Cambridge, Massachusetts headquarters attracts top talent in machine learning and synthetic biology. By combining data‑centric discovery with experimental validation, Nabla Bio positions itself at the forefront of next‑generation drug development.